RecruitingPhase 4NCT02523092
Use of CXCL9 as a Biomarker of Acthar Efficacy
Sponsor
University of California, San Francisco
Enrollment
14 participants
Start Date
Nov 3, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria2
- Biopsy-proven diagnosis of sarcoidosis with demonstrated pulmonary involvement
- Refractoriness to or intolerance of immunosuppressive agents like prednisone or methotrexate
Exclusion Criteria10
- Smoking
- Cancer
- Chronic infections (e.g. tuberculosis, viral, fungal, bacterial)
- Inflammatory conditions
- Coexisting lung disease
- Congestive heart failure
- Uncontrolled hypertension
- Recent surgery
- Active peptic ulcers
- Osteoporosis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGActhar gel
Acthar gel given IM or SQ as per package insert
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02523092
Related Trials
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
NCT004703271 location
EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases
NCT070773041 location
Cardiac Sarcoidosis Randomized Trial
NCT0359375930 locations
Mayo AVC Registry and Biobank
NCT030492542 locations
Virtual Patient Groups for Sarcoidosis Associated Fatigue
NCT070739631 location